Front Page News
Registration Opens for the SMA Patient-Focused Drug Development Meeting with the FDA
Registration is now open for the SMA Patient-Focused Drug Development (PFDD) meeting with the FDA. The PFDD meeting will be held at the College Park […]
Read More ›Spinraza Access Update Webinar
On Tuesday, February 14, at 1:00pm EST (10:00am PST/11:00am MST/12:00pm CST), Cure SMA hosted a webinar updating the community on the status of Spinraza access. […]
Read More ›Cure SMA Launches Community Survey to Address Urgent and Important Issues in SMA Treatment
For the past several years, we’ve been working to collect data and information on our community’s experiences, goals, hopes and challenges. We know that the […]
Read More ›Biogen Presents New ENDEAR Data Showing SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation
Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or […]
Read More ›Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza
With the news today that the first-ever patient has received the first commercial Spinraza dose, we are releasing an updated version of our SMA drug […]
Read More ›SMA Patient-Focused Drug Development Meeting with FDA Set for April 18, 2017
Tuesday, April 18, 2017, has been announced as the date for the SMA Patient-Focused Drug Development Meeting with the FDA. At the Patient Focused Drug […]
Read More ›Cure SMA Assists Hundreds of Families in 2016
Each year, Cure SMA provides thousands of families with vital support and resources to help them live active, engaged and hopeful lives. Our programs provide […]
Read More ›Cure SMA Funding Results in 16 New Research Publications
An important goal of our research funding strategy is to share scientific findings with the broader scientific community. To help accomplish this goal, scientists who […]
Read More ›2016 Research Year-in-Review: An Historic Year for Our Community
This has been an historic year for the SMA community. On December 23, the FDA announced its approval of Spinraza, the first-ever approved treatment for […]
Read More ›Biogen Resources for the SMA Community
Biogen has provided the following update on resources they have made available for the SMA community: Biogen recently announced that the U.S. Food and Drug […]
Read More ›